Brief: Cardiff Oncology Announces First Patient Dosed In A Phase 2 Trial Of Onvansertib In Combination With Irinotecan And 5-Fu In Pancreatic Cancer
08/06/2021 14:25
June 8 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN A PHASE
2
TRIAL OF ONVANSERTIB IN COMBINATION WITH IRINOTECAN AND 5-FU IN
PANCREATIC CANCER
* CARDIFF ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN A PHASE
2
TRIAL OF ONVANSERTIB IN COMBINATION WITH IRINOTECAN AND 5-FU IN
PANCREATIC CANCER
Source text for Eikon: ID:nPn32CT3Ra
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering